Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2021

View Archived Issues

Liver sequencing gives insight into alcoholic, nonalcoholic disease

Knocking down Snai1 rescues right ventricular failure in rats by blockade of EtM transition

CT-7439: a potential first-in-class oral cyclin K glue degrader

DRD2 rs18000497 polymorphism is a pharmacogenetic marker in schizophrenia patients on haloperidol

New EGFR inhibitors identified at Qilu Pharmaceutical

Akebia Therapeutics presents new prolyl 4-hydroxylase inhibitors

Medshine Discovery discovers HBV cccDNA formation inhibitors

Wigen Biomedicine Technology patents G12C mutant GTPase KRAS inhibitors

New TGF-beta receptor type-1 inhibitors described by Adlai Nortye

CTX-III as a prognostic biomarker of fibrosis progression

RLY-2608, novel mutant and isoform selective inhibitor of PI3Kalpha

IntoCell and Ab Studio establish research collaboration to combine antibody and linker capabilities

BenevolentAI nominates preclinical candidate for novel ulcerative colitis target

LIB-01 shows promise in rats with erectile dysfunction

IL-36gamma-based therapy modulates immune response in pancreatic cancer models

Cell-free miRNAs as biomarkers of COVID-19 pneumonia and ARDS

Antidepressant treatment modulates inflammatory cytokine plasma levels in major depression

Exelixis and Storm Therapeutics collaborate to advance novel drug leads for cancer

NLS reports preclinical data on NLS-4 for long COVID

DeoBioSciences reports preclinical data on DBX-31 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...